Detalhe da pesquisa
1.
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Haematologica
; 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38268449
2.
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma.
Future Oncol
; 19(1): 7-17, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36779512
3.
A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.
Br J Haematol
; 199(1): 76-85, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35861370
4.
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.
Blood
; 132(11): 1125-1133, 2018 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30045838
5.
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
Nat Med
; 29(10): 2570-2576, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37783970
6.
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Lancet Haematol
; 10(1): e35-e45, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36400069
7.
The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells.
Biol Blood Marrow Transplant
; 14(5): 499-509, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18410892
8.
IRF2BP2-RARA t(1;17)(q42.3;q21.2) APL blasts differentiate in response to all-trans retinoic acid.
Leuk Lymphoma
; 59(9): 2246-2249, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29350080